EGFR and non-small cell lung carcinoma: Post‐hoc analysis of LUX‐Lung 2, LUX‐Lung 3, and LUX‐Lung 6 indicated that afatinib was active in NSCLC harboring certain types of uncommon EGFR mutations, such as Gly719Xaa, Leu861Gln, and Ser768Ile, but was inactive in NSCLC with T790M and exon 20 insertion mutations.140